Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions, utilising new technology from leading academic institutions.
The company raised a total of £1.2m by way of a placing and subscriptions from institutional investors, existing shareholders, the Board of directors and the management team.
Incanthera’s current lead product is Sol, a topical product for the treatment of solar keratosis and the prevention of skin cancers. The money raised will progress the licensing Sol to a commercial partner and will provide additional working capital for the company.
As well as Sol, Incanthera, which originated from the Institute of Cancer Therapeutics at the University of Bradford, is developing a portfolio of specific cancer-targeting therapeutics.
The Gateley team was led by Corporate partner, Nigel Brown, supported by Rebecca Grisewood, Kate Richards and Poppy Ball.
Nigel Brown commented, “Incanthera have built an exciting portfolio of innovative oncology technologies. We are delighted to have supported them on this deal.”